IGSF8 is amplified in a majority of cancer types, except prostate cancers, where homozygous deletions were detected in 2% of analyzed samples (in 5 out of 244 samples of prostate adenocarcinomas) (Figure 7C). This evidence concerns the gene IGSF8 and prostate cancer.